Drug Response Testing and Repurposing Using Glioblastoma Organoid
NCT06782984
Summary
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.
Eligibility
Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid culture Exclusion Criteria: * patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery * failed to obtain MRI scan after CCRT * patients refusal
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06782984